J&J to acquire Momenta for $6.5B

By The Science Advisory Board staff writers

August 20, 2020 -- Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with a tender offer to purchase all outstanding shares of Momenta for $52.50 per share.

The acquisition will expand Johnson & Johnson's ability to enter the autoantibody-driven disease market. The deal includes full global rights to nipocalimab (M281), a clinically validated anti- neonatal Fc receptor (FCRN) antibody. The drug has received a rare pediatric disease designation from the U.S. Food and Drug Administration. The company expects nipocalimab to help it achieve above-market growth in the mid and long term.

In addition to Momenta's employees and lead asset, Johnson & Johnson will acquire Momenta's full pipeline of clinical and preclinical assets. Johnson & Johnson plans to retain Momenta's presence in Cambridge, MA. The site will increase Johnson & Johnson's existing innovation footprint and capabilities in the greater Boston area.

The deal is expected to close in the second half of 2020.

J&J to provide U.S. with 100M doses of COVID-19 vaccine
Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives...
J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.
J&J's Ebola vaccine approved by EU
Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for...
J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...

Copyright © 2020 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter